311 related articles for article (PubMed ID: 22617734)
41. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
42. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
43. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
[TBL] [Abstract][Full Text] [Related]
44. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
[TBL] [Abstract][Full Text] [Related]
45. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
46. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
47. Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.
Engel-Nitz NM; Hao Y; Becker LK; Gerdes R
J Comp Eff Res; 2015 Aug; 4(4):303-14. PubMed ID: 26274792
[TBL] [Abstract][Full Text] [Related]
48. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.
Hurtaud A; Donnadieu A; Escalup L; Cottu PH; Baffert S
Breast; 2016 Dec; 30():73-79. PubMed ID: 27639032
[TBL] [Abstract][Full Text] [Related]
49. Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
Trogdon JG; Baggett CD; Gogate A; Reeder-Hayes KE; Rotter J; Zhou X; Ekwueme DU; Fairley TL; Wheeler SB
Breast Cancer Res Treat; 2020 Jun; 181(3):653-665. PubMed ID: 32346820
[TBL] [Abstract][Full Text] [Related]
50. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
52. The economic burden of metastatic breast cancer in Spain.
Bermejo de Las Heras B; Cortes Ramon Y Cajal J; Galve Calvo E; de la Haba Rodriguez J; Garcia Mata J; Moreno Anton F; Pelaez Fernandez I; Rodriguez-Lescure A; Rodriguez Sanchez CA; Ruiz-Borrego M; Remak E; Barra M; Rivero M; Soto Alvarez J
Eur J Hosp Pharm; 2020 Jan; 27(1):19-24. PubMed ID: 32064084
[TBL] [Abstract][Full Text] [Related]
53. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis.
Tjokrowidjaja A; Lee CK; Houssami N; Lord S
Intern Med J; 2014 Aug; 44(8):764-70. PubMed ID: 24863750
[TBL] [Abstract][Full Text] [Related]
54. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
55. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Hooiveld MJ; Neven P; Raaijmakers JA; Schellens JH
Eur J Cancer Care (Engl); 2015 May; 24(3):340-54. PubMed ID: 25413216
[TBL] [Abstract][Full Text] [Related]
56. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer.
Ó Céilleachair AJ; Hanly P; Skally M; O'Neill C; Fitzpatrick P; Kapur K; Staines A; Sharp L
Med Care; 2013 Apr; 51(4):339-50. PubMed ID: 23358383
[TBL] [Abstract][Full Text] [Related]
57. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
58. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
59. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States.
Mariotto AB; Etzioni R; Hurlbert M; Penberthy L; Mayer M
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):809-815. PubMed ID: 28522448
[No Abstract] [Full Text] [Related]
60. The economics of health care quality and medical errors.
Andel C; Davidow SL; Hollander M; Moreno DA
J Health Care Finance; 2012; 39(1):39-50. PubMed ID: 23155743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
